DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)
Purpose
This is a 2-arm, randomized, open-label, multicenter, global, Phase 3 trial to evaluate the efficacy, safety, and tolerability of tovorafenib monotherapy versus standard of care (SoC) chemotherapy in participants with pediatric low-grade glioma (LGG) harboring an activating rapidly accelerated fibrosarcoma (RAF) alteration requiring first-line systemic therapy.
Conditions
- Low-grade Glioma
- Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma
- Pediatric Low-grade Glioma
Eligibility
- Eligible Ages
- Under 25 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Less than 25 years of age with LGG with known activating RAF alteration. - Histopathologic diagnosis of glioma or glioneuronal tumor. - At least one measurable lesion as defined by RANO criteria. - Meet indication for first-line systemic therapy.
Exclusion Criteria
- Participant has any of the following tumor-histological findings: 1. Schwannoma 2. Subependymal giant cell astrocytoma (Tuberous Sclerosis) 3. Diffuse intrinsic pontine glioma, even if histologically diagnosed as World Health Organization (WHO) Grade I-II - Participant's tumor has additional pathogenic molecular alterations, including but not limited to a) isocitrate dehydrogenase (IDH) 1/2 mutation, b) Histone H3 mutation, and c) neurofibromatosis Type 1 (NF-1) loss of function alteration. - Known or suspected diagnosis of NF-1/ neurofibromatosis Type 2 (NF-2). - Prior or ongoing nonsurgical anticancer therapy for this indication (eg, chemotherapy, oral/IV targeted therapy) including radiation.
Study Design
- Phase
- Phase 3
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Intervention Model Description
- Tovorafenib versus standard of care chemotherapy
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental Tovorafenib |
|
|
|
Active Comparator Investigator's choice of Standard of care therapy |
|
Recruiting Locations
Birmingham, Alabama 35233
Phoenix, Arizona 85016
Los Angeles, California 90027
Orange, California 92868
San Francisco, California 94158
Aurora, Colorado 80045
Hartford, Connecticut 06106-3322
Washington, District of Columbia 20010
Gainesville, Florida 32610
Orlando, Florida 32806
Atlanta, Georgia 30322
Chicago, Illinois 60611
Indianapolis, Indiana 46202
Boston, Massachusetts 02215
Ann Arbor, Michigan 48109
Minneapolis, Minnesota 55404
Saint Louis, Missouri 63110
Omaha, Nebraska 68198-6878
New York, New York 10016
Rochester, New York 14642
Durham, North Carolina 27705
Cleveland, Ohio 44195
Dallas, Texas 75390
Houston, Texas 77030
Seattle, Washington 98105
Madison, Wisconsin 53792
More Details
- NCT ID
- NCT05566795
- Status
- Recruiting
- Sponsor
- Day One Biopharmaceuticals, Inc.
Detailed Description
Approximately 400 treatment-naïve LGG participants will be randomized 1:1 to either tovorafenib (Arm 1) or an Investigator's choice of SoC chemotherapy (Arm 2). Arm 1 (tovorafenib): Treatment cycles will repeat every 28 days in the absence of disease progression. Participants will continue tovorafenib until any of the following occurs: disease progression, unacceptable toxicity, withdrawal of consent to treatment, or end of study. Arm 2 (Investigator's Choice of SoC Chemotherapy): Participants will receive one of 4 SoC chemotherapy options selected by the treating Investigator: Children's Oncology Group - Vincristine/Carboplatin (COG-V/C) regimen, International Society for Paediatric Oncology - Low-Grade Glioma Vincristine/Carboplatin (SIOPe-LGG-V/C) regimen, vinblastine (VBL) regimen, or monthly carboplatin. The choice of SoC chemotherapy regimen will be selected prior to participant randomization. Treatment will continue until completion of therapy or until any of the following occurs: disease progression, unacceptable toxicity, withdrawal of consent to treatment, or end of study. Participants who discontinue treatment due to disease progression will have (1) radiographic evidence of disease progression, as determined by the Investigator, or (2) clinical progression, as determined by the Investigator. Investigators are encouraged to discuss cases of clinical progression and early radiographic progression without clinical symptoms with the Sponsor Medical Monitor prior to treatment discontinuation or initiation of a different form of treatment for the malignancy. Participants may continue therapy beyond progressive disease (PD).